Compositions and methods for treatment of microbial infections
The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of a protein isolated from bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions.
1. A method of treating a Staphylococcus aureus ( S. aureus ) infection in humans or animals, comprising, administering to a human or animal having said infection, a composition comprising one or more proteins from a 36 kDa fraction isolated from a bacterial lysate derived from the infection of at least one bacterial strain of S. aureus , deposited with the Czech Collection of Microorganisms (CCM) under accession number CCM 4992 with at least one bacteriophage deposited with the Deutsche Sammlung von Mikroorganismen and Zellkulturen GmBH (DSM) having accession number DSM14614, DSM 14615, or DSM 14616.
2. The method of claim 1 , wherein the composition is administered subcutaneously, intradermally, intramuscularly, nasally, or parenterally.
3. The method of claim 1 , wherein the infection comprises chronic upper respiratory disease, mastitis, wound infection, osteomyelitis, endocarditis, skin polymicrobial infections, bronchial asthma, chronic sinusitis, cystic fibrosis or acne vulgaris.
4. The method of claim 1 , further comprising a bacterial lysate derived from at least one bacterial strain deposited with the CCM under accession number CCM 4992, CCM 4993, CCM 4994, CCM 4995, CCM 4996, CCM 4997, or CCM 4998.
5. A method of vaccination for altering a Staphylococcus aureus ( S. aureus ) infection or pathological conditions resulting from said S. aureus infection comprising administering at least one time to a human or animal a composition comprising fructose-bisphosphate aldolase from a 36 kDa fraction isolated from a bacterial lysate derived from the infection of at least one bacterial strain of S. aureus deposited with the Czech Collection of Microorganisms (CCM) under accession number CCM 4992 with a bacteriophage deposited with the Deutsche Sammlung von Mikroorganismen and Zellkulturen GmBH (DSM) having accession number DSM 14614, DSM 14615, or DSM 14616.
6. The method of claim 5 , further comprising a lysate derived from a S. aureus bacterial strain deposited with the CCM under accession number CCM 4992, CCM 4993, CCM 4994, CCM 4995, CCM 4996, CCM 4997, or CCM 4998.
7. The method of claim 5 , wherein the composition is administered subcutaneously, intradermally, intramuscularly, nasally, or parenterally.
8. The composition of claim 1 , wherein the composition is a pharmaceutical composition.
9. The composition of claim 5 , wherein the composition is a pharmaceutical composition.
10. The method of claim 8 , further comprising a bacterial lysate derived from the infection of at least one bacterial strain of S. aureus , deposited with the Czech Collection of Microorganisms (CCM) under accession number CCM 4992 with at least one bacteriophage deposited with the Deutsche Sammlung von Mikroorganismen and Zellkulturen GmBH (DSM) having accession number DSM 14614, DSM 14615, or DSM 14616.
11. The method of claim 5 , further comprising a bacterial lysate derived from the infection of at least one bacterial strain of S. aureus , deposited with the Czech Collection of Microorganisms (CCM) under accession number CCM 4992 with at least one bacteriophage deposited with the Deutsche Sammlung von Mikroorganismen and Zellkulturen GmBH (DSM) having accession number DSM 14614, DSM 14615, or DSM 14616.